Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis by Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi

Get full text

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring Exon21 L858R mutation: a multicenter retrospective obs... by Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Yuki Sato, Yoshiki Negi, Tomohiro Oba, Toshiyuki Sumi, Hirokuni Hirata, Hidemitsu Funabashi, Yuko Oya, Hajime Kikuchi, Naoko Katsurada, Takeshi Nakatani, Keiko Tanimura, Taku Nakagawa, Naoya Takeda, Takahiro Asami, Osamu Honjo, Hiromi Nagashima, Takumi Yamaura, Norihiko Hata, Miyako Kitazono, Naoya Nishioka, Akihiro Tamiya, Yuichi Sakamori, Ryota Shigaki, Kyoichi Kaira, Ryoichi Honda, Takashi Matsui, Eriko Suzuki, Kentaro Ito, Kojiro Otsuka, Naoto Takase, Yusuke Murakami, Kazuhiko Matsuno, Sumito Inoue, Akira Kisohara, Sojiro Kusumoto, Hiroe Aoshima, Yumiko Kakizaki, Akihito Kubo, Akito Hata, Nobuhisa Ishikawa, Kosuke Hamai, Nobuhiro Kanaji, Toshihiro Misumi, Noriyuki Matsutani, Nobuhiko Seki

Get full text